My ePortfolio Register   

ESMO 2017: New prostate data from STAMPEDE

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 1006
Rating:

Prof Martin Bögemann and Prof Nicholas James

This expert to expert discussion focuses on new data from the STAMPEDE trial.

Data released at ESMO 2017 looks to answer whether the addition of abiraterone acetate plus prednisolone (AAP) improves outcomes vs. docetaxel for patients with high risk prostate cancer.

A second abstract then evaluated whether the addition of AAP improves outcomes for patients with M0 disease. 

Both speakers highlight current UK and German approval and reimbursement status and hypothesised that patients would prefer to have hormone based treatments over chemotherapy options despite the increased duration of therapy and routine scheduling of follow up visits.

The experts touch on PSMA radio-tagged diagnostics and the balance of an active dose and minimising patient side effects.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence